FANJ
ATOS icon

Financial Architects (New Jersey)’s Atossa Therapeutics ATOS Stock Holding History

Financial Architects (New Jersey)’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-1
Closed -$19K – 178
2013
Q3 		$19K Buy
+1
New +$13.1K 0.01% 398

Other funds holding ATOS

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

Financial Architects (New Jersey)'s ATOS Position: Q4 2013 in Review

Financial Architects (New Jersey) sold out of Atossa Therapeutics (ATOS) in Q4 2013, closing a stake of 1 share — an estimated $19K sold.

Financial Architects (New Jersey) first reported a position in ATOS in Q3 2013 and held it in 1 quarter. The position peaked at $19K in Q3 2013. 6 funds tracked by Wall St. Rank hold ATOS as of Q4 2013.

  • Financial Architects (New Jersey) reported no remaining Atossa Therapeutics position as of Q4 2013 after selling out during the quarter.
  • Financial Architects (New Jersey) sold 1 Atossa Therapeutics share in Q4 2013, an estimated $19K.
  • Financial Architects (New Jersey) first reported a position in Atossa Therapeutics in Q3 2013 and held it in 1 quarter.
  • Financial Architects (New Jersey)'s Atossa Therapeutics position peaked at $19K in Q3 2013.
  • 6 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q4 2013.

Based on Financial Architects (New Jersey)'s 13F filing for Q4 2013, filed 7 Feb 2014.